文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

急性肾损伤自动电子预警对成人患者诊疗与结局的影响:一项随机临床试验

Automated Electronic Alert for the Care and Outcomes of Adults With Acute Kidney Injury: A Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2024-01-02
一句话结论单中心双盲RCT显示,电子AKI预警联合非强制集束化措施未改善肾功能或患者结局,但改变了诊疗行为。

该单中心、双盲、平行组随机临床试验于2019年8月1日至2021年12月31日在中国南京一家三级教学医院开展,纳入18岁以上住院成人AKI患者(按KDIGO肌酐标准定义),1:1随机分为预警组(n=1123)和常规治疗组(n=1085)。主要终点为随机化后7天内eGFR最大变化绝对值,预警组中位数3.7(-6.4至19.3)mL/min/1.73 m2 vs 常规组2.9(-9.2至16.9)mL/min/1.73 m2(P=.24),探索性分析所有亚组结果稳健。预警组静脉输液更多(82.6% vs 61.8%,P<.001)、非甾体抗炎药暴露更少(5.0% vs 11.0%,P<.001)、出院时AKI记录更多(49.9% vs 27.3%,P<.001),但以患者为中心的次要结局无差异。作者认为电子AKI预警未改善肾功能或其他患者中心结局,但改变了诊疗行为,需未来临床实践中将高质量干预与AKI预警结合使用。

要点

  • 单中心双盲RCT纳入2208例住院AKI成人,预警组1123例 vs 常规组1085例,主要终点7天内eGFR最大变化绝对值无差异(3.7 vs 2.9 mL/min/1.73 m2,P=.24)。
  • 预警组静脉输液更多(927例[82.6%] vs 670例[61.8%],P<.001),非甾体抗炎药暴露更少(56例[5.0%] vs 119例[11.0%],P<.001)。
  • 预警组出院时AKI记录率更高(560例[49.9%] vs 296例[27.3%],P<.001)。
  • 以患者为中心的次要结局(死亡、透析、AKI进展、AKI恢复)两组间无差异。
  • 作者认为需将高质量干预与AKI预警结合用于未来临床实践。

适用人群与场景

  • 纳入标准:18岁及以上住院成人,按改善全球肾脏病预后组织(KDIGO)肌酐标准定义AKI。
  • 随机化按内科vs外科病房、ICU vs非ICU分层,1:1分为预警组或常规治疗组。
  • 分析基于改良意向治疗人群。

诊断标准与关键阈值

  • AKI定义采用KDIGO肌酐标准。

处置流程与药物剂量

  • 预警组:程序化AKI预警系统自动生成随机化并向临床医生手机发送消息;常规治疗组不发送消息。
  • AKI预警伴随集束化措施,由一般性、非个体化、非强制的AKI管理措施组成。

研究设计与关键结果

  • 研究类型:单中心、双盲、平行组随机临床试验,2019年8月1日至2021年12月31日在中国南京一家三级教学医院开展,共2208例患者(中位[IQR]年龄65[54-72]岁;男性1560例[70.7%])随机分为预警组(n=1123)和常规治疗组(n=1085)并纳入分析。
  • 主要终点:随机化后7天内eGFR最大变化绝对值中位数(IQR)预警组3.7(-6.4至19.3)mL/min/1.73 m2 vs 常规组2.9(-9.2至16.9)mL/min/1.73 m2,P=.24;探索性分析所有亚组结果稳健。
  • 以诊疗为中心的结局:预警组静脉输液更多(927[82.6%] vs 670[61.8%];P<.001),非甾体抗炎药暴露更少(56[5.0%] vs 119[11.0%];P<.001),出院时AKI记录更多(560[49.9%] vs 296[27.3%];P<.001)。
  • 以患者为中心的次要结局(死亡、透析、AKI进展、AKI恢复)两组间无差异。

证据类型、等级与局限

  • 证据类型:单中心、双盲、平行组随机临床试验;试验注册号ClinicalTrials.gov NCT03736304。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为电子AKI预警未改善肾功能或其他患者中心结局,但改变了诊疗行为,需未来临床实践中将高质量干预与AKI预警结合使用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Despite the expansion of published electronic alerts for acute kidney injury (AKI), there are still concerns regarding their effect on the clinical outcomes of patients.

OBJECTIVE: To evaluate the effect of the AKI alert combined with a care bundle on the care and clinical outcomes of patients with hospital-acquired AKI.

DESIGN, SETTING, AND PARTICIPANTS: This single-center, double-blind, parallel-group randomized clinical trial was conducted in a tertiary teaching hospital in Nanjing, China, from August 1, 2019, to December 31, 2021. The inclusion criteria were inpatient adults aged 18 years or older with AKI, which was defined using the Kidney Disease: Improving Global Outcomes creatinine criteria. Participants were randomized 1:1 to either the alert group or the usual care group, which were stratified by medical vs surgical ward and by intensive care unit (ICU) vs non-ICU setting. Analyses were conducted on the modified intention-to-treat population.

INTERVENTIONS: A programmatic AKI alert system generated randomization automatically and sent messages to the mobile telephones of clinicians (alert group) or did not send messages (usual care group). A care bundle accompanied the AKI alert and consisted of general, nonindividualized, and nonmandatory AKI management measures.

MAIN OUTCOMES AND MEASURES: The primary outcome was maximum change in estimated glomerular filtration rate (eGFR) within 7 days after randomization. Secondary patient-centered outcomes included death, dialysis, AKI progression, and AKI recovery. Care-centered outcomes included diagnostic and therapeutic interventions for AKI.

RESULTS: A total of 2208 patients (median [IQR] age, 65 [54-72] years; 1560 males [70.7%]) were randomized to the alert group (n = 1123) or the usual care group (n = 1085) and analyzed. Within 7 days of randomization, median (IQR) maximum absolute changes in eGFR were 3.7 (-6.4 to 19.3) mL/min/1.73 m2 in the alert group and 2.9 (-9.2 to 16.9) mL/min/1.73 m2 in the usual care group (P = .24). This result was robust in all subgroups in an exploratory analysis. For care-centered outcomes, patients in the alert group had more intravenous fluids (927 [82.6%] vs 670 [61.8%]; P < .001), less exposure to nonsteroidal anti-inflammatory drugs (56 [5.0%] vs 119 [11.0%]; P < .001), and more AKI documentation at discharge (560 [49.9%] vs 296 [27.3%]; P < .001) than patients in the usual care group. No differences were observed in patient-centered secondary outcomes between the 2 groups.

CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial showed that the electronic AKI alert did not improve kidney function or other patient-centered outcomes but changed patient care behaviors. The findings warrant the use of a combination of high-quality interventions and AKI alert in future clinical practice.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03736304.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Li T, Wu B, Li L, et al. Automated Electronic Alert for the Care and Outcomes of Adults With Acute Kidney Injury: A Randomized Clinical Trial. JAMA Netw Open. 2024. PMID: 38241047. doi:10.1001/jamanetworkopen.2023.51710

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。